TSE:APS

Aptose Biosciences - APS Stock Forecast, Price & News

C$1.08

-0.01 (-0.92%)

(As of 08/19/2022 12:00 AM ET)

Add

Compare

Today's Range: C$1.08
▼
C$1.11
50-Day Range: C$0.93
▼
C$1.17
52-Week Range: C$0.90
▼
C$3.91

Volume: 6,055 shs
Average Volume: 29,803 shs
Market Capitalization: C$99.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$8.50

Aptose Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 687.0% Upside
C$8.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
C$3,376 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Aptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of C$8.50, Aptose Biosciences has a forecasted upside of 687.0% from its current price of C$1.08.
Amount of Analyst Coverage
Aptose Biosciences has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for APS.

0.0

Dividend Strength

Dividend Yield
Aptose Biosciences does not currently pay a dividend.
Dividend Growth
Aptose Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APS.

0.6

News and Social Media Coverage

MarketBeat Follows
1 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptose Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$3,376.00 in company stock and sold C$0.00 in company stock.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Aptose Biosciences is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aptose Biosciences is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aptose Biosciences has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aptose Biosciences (TSE:APS) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Aptose Biosciences Price Performance

Shares of APS Stock traded down C$0.02 during trading hours on Friday, reaching C$1.07. The company had a trading volume of 6,055 shares, compared to its average volume of 29,803. Aptose Biosciences has a 12-month low of C$0.90 and a 12-month high of C$3.91. The company has a debt-to-equity ratio of 0.72, a quick ratio of 6.70 and a current ratio of 6.89. The company has a market capitalization of C$98.76 million and a price-to-earnings ratio of -1.26. The stock has a fifty day moving average of C$1.06 and a 200-day moving average of C$1.33.

Analyst Upgrades and Downgrades

Separately, Jonestrading restated a "buy" rating and issued a C$5.00 price objective on shares of Aptose Biosciences in a report on Friday, June 3rd.

Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Stock News Headlines

August 6, 2022 | americanbankingnews.com

Aptose Biosciences Inc. (TSE:APS) to Post FY2022 Earnings of ($0.58) Per Share, Cantor Fitzgerald Forecasts

August 6, 2022 | americanbankingnews.com

Research Analysts Offer Predictions for Aptose Biosciences Inc.'s Q3 2022 Earnings (TSE:APS)

July 23, 2022 | finance.yahoo.com

Is Aptose Biosciences (TSE:APS) In A Good Position To Invest In Growth?

July 19, 2022 | finance.yahoo.com

Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

May 9, 2022 | finance.yahoo.com

Aptose Reports Results for the First Quarter 2022

May 4, 2022 | finance.yahoo.com

Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

March 8, 2022 | finance.yahoo.com

Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

March 1, 2022 | finance.yahoo.com

Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference

December 16, 2021 | msn.com

Aptose Biosciences Climbs 17% to Reclaim Some Losses

December 15, 2021 | finance.yahoo.com

Insiders who purchased this year lose US$89k as Aptose Biosciences Inc. (TSE:APS) stock drops to CA$1.44

December 13, 2021 | finance.yahoo.com

HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

November 26, 2021 | finance.yahoo.com

Implied Volatility Surging for Aptose Biosciences (APTO) Stock Options

November 24, 2021 | finance.yahoo.com

Why Investors Should Hold on to Universal Health (UHS) Stock

November 22, 2021 | finance.yahoo.com

Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference

November 11, 2021 | finance.yahoo.com

Aptose Reports Results for the Third Quarter 2021

November 4, 2021 | finance.yahoo.com

Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting

August 19, 2021 | finance.yahoo.com

AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints

August 18, 2021 | finance.yahoo.com

Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review

August 6, 2021 | finance.yahoo.com

Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

August 3, 2021 | finance.yahoo.com

Aptose Reports Results for the Second Quarter 2021

August 2, 2021 | finance.yahoo.com

We Think Aptose Biosciences (TSE:APS) Can Afford To Drive Business Growth

July 26, 2021 | finance.yahoo.com

Were Hedge Funds Right About Cutera, Inc. (CUTR)?

July 20, 2021 | finance.yahoo.com

Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021

July 19, 2021 | finance.yahoo.com

Hedge Funds Are Crazy About Aptose Biosciences Inc (APTO)

June 22, 2021 | ca.finance.yahoo.com

3 TSX Stocks Bay Street Expects Could Double or Triple in 1 Year!

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Company Calendar

Today: 8/20/2022
Next Earnings (Estimated): 11/10/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:APS
CUSIP: N/A
CIK: N/A
Web: aptose.com
Phone: +1-647-4799828
Fax: N/A
Employees: 31
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: C$8.50
High Stock Price Forecast: C$12.00
Low Stock Price Forecast: C$5.00
Forecasted Upside/Downside: +687.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.72
Current Ratio: 6.89
Quick Ratio: 6.70

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$0.70 per share
Price / Cash Flow: 1.55
Book Value: C$0.60 per share
Price / Book: 1.80

Miscellaneous

Outstanding Shares: 92,295,000
Free Float: N/A
Market Cap: C$99.68 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. William G. Rice Ph.D. (Age 59)
Chairman, Pres & CEO

Mr. Gregory K. Chow CPA (Age 45)
MBA, BA, Sr. VP, CFO & Principal Accounting Officer

Mr. Ernest Kitt B.S.
M.S, VP of Devel. & Technical Operations

Dr. Stephen B. Howell (Age 73)
Chief Medical Officer

Mr. Peter Murray
Director of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APS Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APS shares.
View APS analyst ratings or view top-rated stocks.
What is Aptose Biosciences' stock price forecast for 2022?: 3 Wall Street research analysts have issued 12 month price objectives for Aptose Biosciences' shares. Their APS share price forecasts range from C$5.00 to C$12.00. On average, they anticipate the company's share price to reach C$8.50 in the next year. This suggests a possible upside of 694.4% from the stock's current price.
View analysts price targets for APS or view top-rated stocks among Wall Street analysts.
How have APS shares performed in 2022?: Aptose Biosciences' stock was trading at C$1.73 at the beginning of the year. Since then, APS shares have decreased by 38.2% and is now trading at C$1.07.
View the best growth stocks for 2022 here.
When is Aptose Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our APS earnings forecast.

What other stocks do shareholders of Aptose Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD).
What is Aptose Biosciences' stock symbol?: Aptose Biosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APS."
How do I buy shares of Aptose Biosciences?: Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Aptose Biosciences' stock price today?: One share of APS stock can currently be purchased for approximately C$1.07.
How much money does Aptose Biosciences make?: Aptose Biosciences (TSE:APS) has a market capitalization of C$98.76 million.
How can I contact Aptose Biosciences?: Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The official website for the company is aptose.com. The biotechnology company can be reached via phone at +1-647-4799828.

This page (TSE:APS) was last updated on 8/20/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Aptose Biosciences - APS Stock Forecast, Price & News

Aptose Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Aptose Biosciences (TSE:APS) Stock

Aptose Biosciences Price Performance

Analyst Upgrades and Downgrades

APS Stock News Headlines

APS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

APS Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™